118 related articles for article (PubMed ID: 24691494)
1. Adherence therapy following acute exacerbation of schizophrenia: A randomised controlled trial in Thailand.
von Bormann S; Robson D; Gray R
Int J Soc Psychiatry; 2015 Feb; 61(1):3-9. PubMed ID: 24691494
[TBL] [Abstract][Full Text] [Related]
2. Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial.
Schulz M; Gray R; Spiekermann A; Abderhalden C; Behrens J; Driessen M
Schizophr Res; 2013 May; 146(1-3):59-63. PubMed ID: 23452506
[TBL] [Abstract][Full Text] [Related]
3. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.
Maneesakorn S; Robson D; Gournay K; Gray R
J Clin Nurs; 2007 Jul; 16(7):1302-12. PubMed ID: 17584349
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
[TBL] [Abstract][Full Text] [Related]
5. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
6. An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia.
Anderson KH; Ford S; Robson D; Cassis J; Rodrigues C; Gray R
Int J Ment Health Nurs; 2010 Oct; 19(5):340-9. PubMed ID: 20887608
[TBL] [Abstract][Full Text] [Related]
7. Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT.
Morrison AP; Pyle M; Gumley A; Schwannauer M; Turkington D; MacLennan G; Norrie J; Hudson J; Bowe S; French P; Hutton P; Byrne R; Syrett S; Dudley R; McLeod HJ; Griffiths H; Barnes TR; Davies L; Shields G; Buck D; Tully S; Kingdon D
Health Technol Assess; 2019 Feb; 23(7):1-144. PubMed ID: 30806619
[TBL] [Abstract][Full Text] [Related]
8. Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.
Crawford MJ; Thana L; Evans R; Carne A; O'Connell L; Claringbold A; Saravanamuthu A; Case R; Munjiza J; Jayacodi S; Reilly JG; Hughes E; Hoare Z; Barrett B; Leeson VC; Paton C; Keown P; Pappa S; Green C; Barnes TR
Health Technol Assess; 2020 Sep; 24(44):1-54. PubMed ID: 32930090
[TBL] [Abstract][Full Text] [Related]
9. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial.
Morrison AP; Turkington D; Pyle M; Spencer H; Brabban A; Dunn G; Christodoulides T; Dudley R; Chapman N; Callcott P; Grace T; Lumley V; Drage L; Tully S; Irving K; Cummings A; Byrne R; Davies LM; Hutton P
Lancet; 2014 Apr; 383(9926):1395-403. PubMed ID: 24508320
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
[TBL] [Abstract][Full Text] [Related]
12. Adherence therapy for people with schizophrenia. European multicentre randomised controlled trial.
Gray R; Leese M; Bindman J; Becker T; Burti L; David A; Gournay K; Kikkert M; Koeter M; Puschner B; Schene A; Thornicroft G; Tansella M
Br J Psychiatry; 2006 Dec; 189():508-14. PubMed ID: 17139034
[TBL] [Abstract][Full Text] [Related]
13. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia: cluster randomised controlled trial.
Gray R; Wykes T; Edmonds M; Leese M; Gournay K
Br J Psychiatry; 2004 Aug; 185():157-62. PubMed ID: 15286068
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
Barnes TR; Leeson VC; Paton C; Costelloe C; Simon J; Kiss N; Osborn D; Killaspy H; Craig TK; Lewis S; Keown P; Ismail S; Crawford M; Baldwin D; Lewis G; Geddes J; Kumar M; Pathak R; Taylor S
Health Technol Assess; 2016 Apr; 20(29):1-46. PubMed ID: 27094189
[TBL] [Abstract][Full Text] [Related]
16. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial.
Moritz S; Veckenstedt R; Andreou C; Bohn F; Hottenrott B; Leighton L; Köther U; Woodward TS; Treszl A; Menon M; Schneider BC; Pfueller U; Roesch-Ely D
JAMA Psychiatry; 2014 Oct; 71(10):1103-11. PubMed ID: 25103718
[TBL] [Abstract][Full Text] [Related]
17. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial.
Morrison AP; Pyle M; Gumley A; Schwannauer M; Turkington D; MacLennan G; Norrie J; Hudson J; Bowe SE; French P; Byrne R; Syrett S; Dudley R; McLeod HJ; Griffiths H; Barnes TRE; Davies L; Kingdon D;
Lancet Psychiatry; 2018 Aug; 5(8):633-643. PubMed ID: 30001930
[TBL] [Abstract][Full Text] [Related]
18. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
19. Cognitive-behavioural therapy for patients with schizophrenia: a multicentre randomized controlled trial in Beijing, China.
Li ZJ; Guo ZH; Wang N; Xu ZY; Qu Y; Wang XQ; Sun J; Yan LQ; Ng RM; Turkington D; Kingdon D
Psychol Med; 2015 Jul; 45(9):1893-905. PubMed ID: 25532460
[TBL] [Abstract][Full Text] [Related]
20. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder.
Byerly MJ; Fisher R; Carmody T; Rush AJ
J Clin Psychiatry; 2005 Aug; 66(8):997-1001. PubMed ID: 16086614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
